Skip to main content
Erschienen in: Rheumatology International 11/2015

01.11.2015 | Short Communication - Health Services Research

Factors associated with the intensification of treatment in rheumatoid arthritis in clinical practice

verfasst von: Antonio Naranjo, Laura Cáceres, José Ángel Hernández-Beriaín, Félix Francisco, Soledad Ojeda, Sigrid Talaverano, Javier Nóvoa-Medina, José Adán Martín, Esmeralda Delgado, Elisa Trujillo, Fátima Álvarez, Laura Magdalena, Carlos Rodríguez-Lozano

Erschienen in: Rheumatology International | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

The aim of the present study was to analyse the patterns of treatment adjustment in rheumatoid arthritis (RA) patients with active disease in routine clinical care. This was a cross-sectional study of consecutive patients with RA conducted in five hospitals. Activity scales (DAS28-ESR) and function (HAQ) were measured, as well as whether ultrasound was performed as part of the assessment. Treatment decision (no changes/reduction/intensification) and time to the next scheduled visit were the outcomes variables. Associated factors were analysed by multilevel regression models. A total of 343 patients were included (77 % women, mean age 57 years, mean RA duration 10 years), of whom 44 % were in remission by DAS28. Treatment was continued in 202 (59 %) patients, reduced in 57 (16 %), and intensified in 83 (24 %). In the 117 patients with active RA (DAS28 ≥ 3.2), treatment was intensified in 61 (52 %). Factors associated with treatment intensification were physician and patient VAS, and DAS28, but not the centre. In the multilevel regression analysis with intensification of treatment as dependent variable, the following factors were significantly associated: DAS28 [OR 3.67 (95 % CI 2.43–5.52)], patient VAS [OR 1.04 (95 % CI 1.01–1.08)], and have performed an ultrasound [OR 3.36 (95 % CI 1.47–7.68)]. Factors associated with time to the next scheduled visit (an average of 4.3 months) were patient and physician VAS, DAS28, and centre. In clinical practice, half of the patients with active RA maintain or reduce the treatment. The decision to intensify treatment in active RA as recommended by a treat-to-target strategy is complex in practice.
Literatur
1.
Zurück zum Zitat Smolen JS, Aletaha D, Bijlsma JW, T2T Expert Committee et al (2011) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 70:1519CrossRef Smolen JS, Aletaha D, Bijlsma JW, T2T Expert Committee et al (2011) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 70:1519CrossRef
2.
Zurück zum Zitat Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L (2014) Review: treat to target in rheumatoid arthritis: Fact, fiction, or hypothesis? Arthritis Rheumatol 66:775–782CrossRefPubMedCentralPubMed Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L (2014) Review: treat to target in rheumatoid arthritis: Fact, fiction, or hypothesis? Arthritis Rheumatol 66:775–782CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat Pyne L, Bykerk VP, Boire G et al (2012) Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH study. J Rheumatol 39:2081–2087CrossRefPubMed Pyne L, Bykerk VP, Boire G et al (2012) Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH study. J Rheumatol 39:2081–2087CrossRefPubMed
4.
Zurück zum Zitat Dougados M, Nataf H, Steinberg G, Rouanet S, Falissard B (2013) Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study. Rheumatology (Oxford) 52:391–399CrossRef Dougados M, Nataf H, Steinberg G, Rouanet S, Falissard B (2013) Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study. Rheumatology (Oxford) 52:391–399CrossRef
5.
Zurück zum Zitat Pincus T, Castrejón I (2013) Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull Hosp Jt Dis 71(Suppl 1):S33–S40 Pincus T, Castrejón I (2013) Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target. Bull Hosp Jt Dis 71(Suppl 1):S33–S40
6.
Zurück zum Zitat Vermeer M, Kuper HH, Bernelot Moens HJ, Hoekstra M, Posthumus MD, van Riel PL, van de Laar MA (2012) Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther 14:R254CrossRefPubMedCentralPubMed Vermeer M, Kuper HH, Bernelot Moens HJ, Hoekstra M, Posthumus MD, van Riel PL, van de Laar MA (2012) Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Res Ther 14:R254CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Caporali R, Conti F, Covelli M, Govoni M, Salaffi F, Ventriglia G, Montecucco C (2014) Treating rheumatoid arthritis to target: an Italian rheumatologists’ survey on the acceptance of the treat-to-target recommendations. Clin Exp Rheumatol 32(4):471–476PubMed Caporali R, Conti F, Covelli M, Govoni M, Salaffi F, Ventriglia G, Montecucco C (2014) Treating rheumatoid arthritis to target: an Italian rheumatologists’ survey on the acceptance of the treat-to-target recommendations. Clin Exp Rheumatol 32(4):471–476PubMed
8.
Zurück zum Zitat Haraoui B, Smolen JS, Aletaha D et al (2011) Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire. Ann Rheum Dis 70(11):1999–2002CrossRefPubMedCentralPubMed Haraoui B, Smolen JS, Aletaha D et al (2011) Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire. Ann Rheum Dis 70(11):1999–2002CrossRefPubMedCentralPubMed
9.
Zurück zum Zitat Cardiel MH (2013) Treat to target strategy in rheumatoid arthritis: real benefits. Reumatol Clin 9:101–105CrossRefPubMed Cardiel MH (2013) Treat to target strategy in rheumatoid arthritis: real benefits. Reumatol Clin 9:101–105CrossRefPubMed
10.
Zurück zum Zitat Kaneko Y, Koike T, Oda H et al (2015) Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan. Mod Rheumatol 25:43–49CrossRefPubMed Kaneko Y, Koike T, Oda H et al (2015) Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan. Mod Rheumatol 25:43–49CrossRefPubMed
11.
Zurück zum Zitat Wolfe F, Michaud K (2007) Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients’ treatment choices. Arthritis Rheum 56:2135–2142CrossRefPubMed Wolfe F, Michaud K (2007) Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients’ treatment choices. Arthritis Rheum 56:2135–2142CrossRefPubMed
12.
Zurück zum Zitat Pope J, Thorne C, Cividino A, Lucas K (2012) Effect of rheumatologist education on systematic measurements and treatment decisions in rheumatoid arthritis: the metrix study. J Rheumatol 39:2247–2252CrossRefPubMed Pope J, Thorne C, Cividino A, Lucas K (2012) Effect of rheumatologist education on systematic measurements and treatment decisions in rheumatoid arthritis: the metrix study. J Rheumatol 39:2247–2252CrossRefPubMed
13.
Zurück zum Zitat de Wit MP, Smolen JS, Gossec L, van der Heijde DM (2011) Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann Rheum Dis 70:891–895CrossRefPubMedCentralPubMed de Wit MP, Smolen JS, Gossec L, van der Heijde DM (2011) Treating rheumatoid arthritis to target: the patient version of the international recommendations. Ann Rheum Dis 70:891–895CrossRefPubMedCentralPubMed
14.
Zurück zum Zitat Naranjo A, Jiménez-Núñez FG, Medina-Luezas J, Senabre JM, Rodríguez-García A, Vázquez M, Santos-Ramírez C, de Buergo MA, López-Lasanta M, Loza E (2012) Impact of the use of musculoskeletal ultrasound by rheumatologists in patients with shoulder and hand complaints compared with traditional clinical care. Clin Exp Rheumatol 30:768–771PubMed Naranjo A, Jiménez-Núñez FG, Medina-Luezas J, Senabre JM, Rodríguez-García A, Vázquez M, Santos-Ramírez C, de Buergo MA, López-Lasanta M, Loza E (2012) Impact of the use of musculoskeletal ultrasound by rheumatologists in patients with shoulder and hand complaints compared with traditional clinical care. Clin Exp Rheumatol 30:768–771PubMed
15.
Zurück zum Zitat Wakefield RJ, D’Agostino MA, Naredo E et al (2012) After treat-to-target: Can a targeted ultrasound initiative improve RA outcomes? Ann Rheum Dis 71:799–803CrossRefPubMed Wakefield RJ, D’Agostino MA, Naredo E et al (2012) After treat-to-target: Can a targeted ultrasound initiative improve RA outcomes? Ann Rheum Dis 71:799–803CrossRefPubMed
16.
Zurück zum Zitat Dale J, Purves D, McConnachie A, McInnes I, Porter D (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res (Hoboken) 66:19–26CrossRef Dale J, Purves D, McConnachie A, McInnes I, Porter D (2014) Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. Arthritis Care Res (Hoboken) 66:19–26CrossRef
Metadaten
Titel
Factors associated with the intensification of treatment in rheumatoid arthritis in clinical practice
verfasst von
Antonio Naranjo
Laura Cáceres
José Ángel Hernández-Beriaín
Félix Francisco
Soledad Ojeda
Sigrid Talaverano
Javier Nóvoa-Medina
José Adán Martín
Esmeralda Delgado
Elisa Trujillo
Fátima Álvarez
Laura Magdalena
Carlos Rodríguez-Lozano
Publikationsdatum
01.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 11/2015
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-015-3332-z

Weitere Artikel der Ausgabe 11/2015

Rheumatology International 11/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.